PLB1004 is named as a drug or biological intervention in 7 clinical trials in our China and USA trial registers, 3 of which are recruiting. Lead sponsors include Avistone Biotechnology Co., Ltd. (5), Beijing Pearl Biotechnology Limited Liability Company (1) and Avistone Pharmaceutical๏ผNingbo๏ผCo., LTD. (1). Registered phases: Phase 2, Phase 1/2, Phase 1 and Phase 3. Conditions studied include Non-Small-Cell Lung Cancer; Non-Small Cell Lung Cancer; NSCLC (Non-small Cell Lung Cancer).
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Non-Small-Cell Lung Cancer | 3 |
| Non-Small Cell Lung Cancer | 2 |
| NSCLC (Non-small Cell Lung Cancer) | 2 |
| EGFR Mutation | 1 |
| Metastatic Lung Cancer | 1 |
| MET Alteration | 1 |
| Lead sponsor | Trials |
|---|---|
| Avistone Biotechnology Co., Ltd. | 5 |
| Beijing Pearl Biotechnology Limited Liability Company | 1 |
| Avistone Pharmaceutical๏ผNingbo๏ผCo., LTD. | 1 |
| Register | PLB1004 trials |
|---|---|
| Clinical trials in China | 5 |
| Clinical trials in USA | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how PLB1004 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists PLB1004 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.